Allelic Combinations of Immune-Response Genes Associated with Glatiramer Acetate Treatment Response in Russian Multiple Sclerosis Patients

Authors:

Abstract
Glatiramer acetate (GA) is widely used as a first-line disease-modifying treatment for multiple sclerosis (MS). However, a significant proportion of MS patient appears to experience modest benefit from GA-treatment. Genetic variants affecting the clinical response to GA are believed to be relevant as biomarkers of GA-treatment efficiency. Nine polymorphisms in candidate genes were analyzed as possible determinants of GA response in 285 Russian MS patients. Special attention was given to identification of response-associated allelic combinations by means of the APSampler algorithm. No significant associations were found for individual polymorphisms. Alleles DRB1*15, TGFB1*T, CCR5*d and IFNAR1*G were the components of the combinations, of which carriage was significantly higher in nonresponders than in responders. Carriers of the most significant combinations: DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G and DRB1*15 + TGFB1*T + CCR5*d (permutation p-values: 0.0056 and 0.013, respectively) had a 14 to 15-times increased risk of ineffective response to GA therapy. The results suggest that the influence of immune-response genes on GA-induced response has a polygenic nature. The data are interpreted as evidence of additive and epistatic influences of the genes on GA efficiency for MS treatment.
Funding Information
  • Russian Foundation for Basic Research (08-04-01834a)
  • Russian Foundation for Basic Research (11-04-01644-a)
  • Russian Foundation for Basic Research (11-04-02016-a)
  • European Community’s Seventh Framework Programme (FP7/2007-2013)
  • European Community’s Seventh Framework Programme (N 212877)
  • Johns Hopkins University Framework for the Future and NIH/NLM (LM008932)

This publication has 49 references indexed in Scilit: